Our Services

Pediatric epilepsy

Directors:
Marcelo Lancman, MD, and Eric Segal, M.D.

Medical Staff:
Lorraine M. Lazar, M.D., Ph.D.
José Serruya, MD
Firas Taha, M.D.

Program Description:
• Our Pediatric Epilepsy Program specializes in evaluating and treating children with epilepsy. Our program is built on the understanding that a child with epilepsy and his or her family encounter special challenges that often require a team of professionals.  Our team includes child neurologists with specialty training in epilepsy neurosurgeons, a psychiatrist, nurses, psychologists, neuropsychologists, and Epilepsy Free scholarships. Our Pediatric Epilepsy team works as a unit to simultaneously provide exceptional medical care, psychological support, educational assistance, and social and community activities. 

• Specialty programs:
* Medical treatment programs
   - Approved seizure medications
   - Experimental seizures medications (not available on the market)
* Surgical treatment program
* Tuberous Sclerosis Specialty Center
* Dravet Syndrome Specialty Center
* Sturge-Weber Specialty Center

Open Research Studies:
- A Multicenter, Randomized, double-blind, parallel group, placebo- controlled trial of two fixed doses of ZX008 (Fenfluramine hydrochloride) oral solution as an adjunctive therapy in children and young adults with Dravet Syndrome.

- 1042-0900: A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children with PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Extension

- An Open-Label, Multicenter study with an Extension Phase to Evaluate the Safety , Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral suspension when Administered as an Adjunctive Therapy in pediatric Subjects (Age 4 to less than 12years) with inadequately Controlled Partial-Onset Seizures or Primary generalized Tonic-Clonic seizures

- A randomized, double-blind, placebo- controlled study to investigate the safety and efficacy of cannabidiol (GWP42003-P) in children and young adults with Dravet Syndrome

Our physicians' scientific publications:

- Diagnostic Yield of Epilepsy Panels in Children With Medication-Refractory Epilepsy

- Effect of treatment of obstructive sleep apnea on seizure outcomes in children with epilepsy

- Biomarkers aiding diagnosis of atypical presentation of pyridoxine-dependent epilepsy

- Chorea associated with antiphospholipid antibodies in a patient with Kabuki syndrome

- Seizures from valproate-carbapenem interaction

- Clinically significant bradyarrhythmias in video-EEG patients

- Lazar, L.M., Milrod, L.M., Solomon, G.E., Labar, D.R. Asynchronous pentobarbital-induced burst suppression with corpus callosum hemorrhage. Clin Neurophysiol 1999; 110(6): 1036-40.

- Harden, C.L., Lazar, L.M., Pick, L.H., Nikolov, B., Goldstein, M.A., Ravdin, L.D., Kocsis, J.H., Labar, D.R. A beneficial effect on mood in partial epilepsy patients treated with gabapentin.  Epilepsia 1999; 40(8): 1129-34.

- Trifiletti, R.R., Lazar, L.M., Bojko, A., Chutorian, A.M., DiMauro, S. Early poliodystrophy with mitochondrial defect: two cases.  Child Neurology Society Abstr 1996: 59. (Presented at the 25th annual meeting of the Child Neurology Society, Minneapolis, Minnesota)

- Lazar, L.M., Blum, M. Regional distribution and developmental expression of epidermal growth factor and transforming growth factor-alpha mRNA in mouse brain by a quantitative nuclease protection assay.  J Neurosci 1992; 12(5): 1688-1697.

- Lazar, L.M. Epidermal growth factor and transforming growth factor-alpha gene expression in the normal and neurodegenerate murine central nervous system.  Doctoral dissertation 1992; Mount Sinai School of Medicine of the City University of New York.

- Lazar, L.M., Kelley, K.A., Blum, M. Epidermal growth factor and transforming growth factor-alpha mRNA expression in Purkinje Cell Degeneration and weaver mutant mice.  Soc Neurosci Abstr 1990; 16:999.  (Presented at the 20th annual meeting of the Society for Neuroscience, St. Louis, MO)

To make an appointment: (914) 428-9213 or 201-343-6676